Investor Day 2024
Logotype for Progyny Inc

Progyny (PGNY) Investor Day 2024 summary

Event summary combining transcript, slides, and related documents.

Logotype for Progyny Inc

Investor Day 2024 summary

9 Jul, 2026

Strategic vision and business fundamentals

  • Positioned for significant growth by expanding from fertility into broader women's health, including maternity and menopause, targeting overlooked and underfunded areas of healthcare.

  • Maintains strong fundamentals: high client retention, member satisfaction, profitability, scalability, and margin expansion, with 99% retention by lives and 80+ NPS.

  • Plans to double revenue and 2.5x Adjusted EBITDA by 2028, targeting $2.4B+ revenue, $500M+ Adjusted EBITDA, 20% revenue CAGR, and 25% Adjusted EBITDA CAGR.

  • Growth levers include deeper penetration of existing clients, new client acquisition, TAM expansion into smaller and global markets, and new product launches.

  • Multi-year targets are underpinned by a robust client base, expanding product suite, disciplined financial management, and strategic investments in women's health.

Product innovation and expansion

  • Expanded offerings from fertility to maternity, menopause, pregnancy, postpartum, and other women's health areas, leveraging a platform built for personalized, evidence-based care.

  • New products are designed to address gaps in care, improve outcomes, and reduce costs, with a focus on member experience and provider enablement.

  • Product roadmap includes further expansion into parenting, sexual and pelvic health, and other clinical adjacencies.

  • New products are expected to contribute 8%-10% of revenue by 2028, with higher gross margins than core fertility services.

  • Case rate-based revenue models are being piloted for new services, with significant client interest and early adoption.

Go-to-market and client relationships

  • Diversified go-to-market approach: direct sales, client success-driven upsell, consultant engagement, and partnerships with aggregators, health plans, and benefit consultants.

  • Near 100% client retention, 80%+ client NPS, and 40% of clients actively advocating for the benefit.

  • High pharmacy attachment rates (93%) and growing adoption of new products (15% attachment rate), with ongoing upsell opportunities.

  • Expansion into smaller employer segments, federal, Taft-Hartley, and global markets, leveraging partnerships and tailored distribution models.

  • Clients report improved outcomes, cost savings, and enhanced employee satisfaction, supporting talent attraction and retention.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more